Board of Directors

Gerry BrownGerry Brown

Chairman and Non-Executive Director
Chairman of the Nomination Committee

Gerry Brown joined the Board in 2006 and was appointed Chairman of the Company in June 2006.  He is Chairman of Quintiles Transnational Europe and of NFT Distribution Holdings.  He is also a Senior Independent Director of both Forth Ports plc and Keller plc.  He was formerly Chairman of Upol Ltd and a non-executive director of Vantec Ltd, CH Jones Ltd, Michael Gerson Ltd and Datrontech plc.  His executive career included directorships with Exel Logistics plc, TDG plc and Tibbett & Britten plc.  Age 64.

Crispin SimonCrispin Simon

Chief Executive

Crispin Simon joined the Company in June 1998. After working at NM Rothschild and McKinsey & Company, he gained general management experience at senior executive level with Rexam plc (then Bowater) and then as President of the Endoscopy Division of Smith & Nephew plc, based in Boston, USA. Crispin Simon is a non-executive director of Imperial College Healthcare NHS Trust and a Governor of Port Regis School.  Age 51.

Ian ArdillIan Ardill

Finance Director & Company Secretary

Ian Ardill, appointed to the Board in October 2004, joined Biocompatibles in January 2003 having spent the previous five years working for Novartis Pharmaceuticals in a variety of financial positions covering Financial Accounting, Systems Implementation, and Treasury. Prior to that, he worked for Letheby & Christopher, a subsidiary of Compass Group PLC; NHA International, a sales and management consultancy; and qualified as an accountant with Grant Thornton. He has a BSc in Accounting and Financial Analysis from Warwick University, England.  Age 41.

Jeremy Curnock CookJeremy Curnock Cook

Senior Independent Non-Executive Director

Jeremy Curnock Cook joined the Board in 1990. He is Executive Chairman of International Bioscience Managers Limited, an investment advisory company to the biotechnology industry and Managing Director of IB Managers Pty (Aus), a fund management company. He served as Managing Director of the Rothschild Bioscience Unit from 1987 until his retirement in 2000. Other directorships include: Chairman of Targeted Genetics Inc. (USA), atugen AG (Germany), EACOM Inc. (Canada), and director of Silence Therapeutics (UK), Osteologix Inc (USA), Aegera Therapeutics Inc.(Canada) and Topigen Pharmaceuticals Inc. (Canada). Age 59.

Anne FaireyAnne Fairey

Independent Non-Executive Director

Anne Fairey joined the Board on 1 September 2008. Anne has been Director of Fairey Medical Ltd since 2003. Previously she was Medical Director of Novartis Pharmaceuticals UK Ltd. Anne qualified in Medicine from Southampton University and subsequently completed her Senior Registrar training in Medical Oncology before moving into the pharmaceutical industry in 1992. She was elected a Member of the Faculty of Pharmaceutical Medicine by distinction in 2004 and a Fellow of the Royal College of Physicians in 2006. Age 47.

Sir Thomas HarrisSir Thomas Harris

Independent Non-Executive Director
Chairman of the Renumeration Committee

Thomas Harris joined the Board on 1 November 2005. He is Vice Chairman of Standard Chartered Capital Markets Ltd, a director of SC (Korea) Bank, the UK-India Business Council, IFSL and a Trustee of Asia House. He was Director General of Trade & Investment USA responsible for British business and technology promotion throughout the USA. He served as British Ambassador to Korea in Seoul, Deputy High Commissioner in Lagos, Nigeria and Commercial Counsellor in the British Embassy in Washington DC.  Age 64.

Peter StratfordPeter Stratford

Managing Director, Drug Delivery Division

Peter Stratford was appointed to the Board in September 2002. Peter joined Biocompatibles in January 1990. After completion of development work in contact lens application, he joined the management team of the Cardiovascular Division at its creation in 1993. He took the role of Group Director Research and Development in 1998 and has since transitioned the group to the current drug delivery focus. Peter has a BSc in Chemistry, a MSc in Polymer Synthesis and a PhD in Pharmaceutical Synthesis.  Age 45.

John SylvestorJohn Sylvester

Managing Director, Oncology Products Division

John Sylvester joined the Company in June 2005 and was appointed to the Board on 1 July 2005. His career covers a series of commercial roles for Rio Tinto Zinc plc, ICI plc and English China Clays where he was General Manager for their European and Asian Operations. Previously he was with Baxter Healthcare where he was VP Marketing for their European Medication delivery business.  Age 45.

Anthony WeirAnthony Weir

Independent Non-Executive Director
Chiarman of the Audit Committee

Tony Weir was appointed to the Board on 1 January 2007. Tony has 20 years experience in life sciences including 10 years as Chief Financial Officer at Vernalis plc. Previously he was with PwC, Financial Training Limited and KPMG, has a degree in Mathematics from Oxford University and is a Fellow of the Institute of Chartered Accountants.  Age 48.

© 2010 Biocompatibles UK Ltd - All rights reserved - Site map - Terms & conditions - Accessiblity - Help - Glossary